Selective Reporting of Antibiotic Susceptibility Test Results in Urinary Tract Infections in the Outpatient Setting
NCT03612297 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 64000
Last updated 2018-08-02
Summary
Antibiotic resistance is a serious and increasing worldwide threat to global public health. One of antibiotic stewardship programmes' objectives is to reduce inappropriate broad-spectrum antibiotics' prescription. Selective reporting of antibiotic susceptibility test (AST) results, which consists of reporting to prescribers only few (n=5-6) antibiotics, preferring first-line and narrow-spectrum agents, is one possible strategy advised in recommendations. However, selective reporting of AST has never been evaluated using an experimental design.
This study is a pragmatic, prospective, multicentre, controlled (selective reporting vs usual complete reporting of AST), before-after (year 2019 vs 2017) study. Selective reporting of AST is scheduled to be implemented from September 2018 in the ATOUTBIO group of 21 laboratories for all E. coli identified in urine cultures in adult outpatients, and to be compared to the usual complete AST performed in the EVOLAB group of 20 laboratories. The main objective is to assess the impact of selective reporting of AST for E. coli positive urine cultures in the outpatient setting on the prescription of broad-spectrum antibiotics frequently used for urinary tract infections (amoxicillin-clavulanate, third generation cephalosporins and fluoroquinolones). The primary endpoint is the after (2019) - before (2017) difference in prescription rates for the previously mentioned antibiotics/classes that will be compared between the two laboratory groups, using linear regression models. Secondary objectives are to evaluate the feasibility of selective reporting of AST implementation by French laboratories and their acceptability by organising focus groups and individual semi-structured interviews with general practitioners and laboratory professionals.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Selective reporting of Antibiotic Susceptibility Tests
Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
Sponsors & Collaborators
-
University of Lorraine
collaborator OTHER -
Central Hospital, Nancy, France
lead OTHER
Principal Investigators
-
Céline Pulcini, Professor · Central Hospital, Nancy, France
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-01
- Primary Completion
- 2019-12-31
- Completion
- 2020-04-30
More Related Trials
-
Modified Reporting From Indwelling Catheters
NCT03488355 ·Status: COMPLETED ·Phase: NA
-
Diagnostic Performance of Plasma Procalcitonin for the Detection of Blood Cultures Contaminations
NCT04573894 ·Status: COMPLETED
-
Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)
NCT00235690 ·Status: COMPLETED ·Phase: NA
-
Dissemination and Implementation of a Videoconference Antimicrobial Stewardship Team
NCT05319561 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety Study of Short-term Antibiotic for Pyelonephritis in Women
NCT01390623 ·Status: COMPLETED ·Phase: PHASE4
-
Detection of Colistin-resistant Isolates From Patients of Intensive Care Units and Oncohaematology Wards.
NCT03971877 ·Status: COMPLETED
-
Clinical Usefulness of Therapeutic Drug Monitoring of Colistin in Patients Treated With Colistin.
NCT03007290 ·Status: COMPLETED ·Phase: NA
-
Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
NCT00414362 ·Status: COMPLETED
-
Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
NCT06069206 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics and Safety of Antimicrobial Agents Administered by Subcutaneous Route in Patients AGEd Over 65 Years
NCT03583749 ·Status: UNKNOWN
-
Personalized Optimization of Antibiotic Therapy in Pulmonary Sepsis Critically Ill Patients Through Application of Rapid Microbiological Diagnostic Technologies and Pharmacokinetic/Pharmacodynamic Modelling
NCT06956053 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Early Oral Switch for Uncomplicated Gram-negative Bacteraemia
NCT05199324 ·Status: RECRUITING ·Phase: PHASE4
-
Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria
NCT01060891 ·Status: COMPLETED ·Phase: PHASE1
-
Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
NCT06652126 ·Status: RECRUITING
-
Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.
NCT04995133 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
NCT05210439 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Clinical Decision Support Tools for Antibiotic Prescribing
NCT03580603 ·Status: COMPLETED ·Phase: NA
-
Clinical Impact of Rapid AST Directly From Blood Cultures
NCT03992703 ·Status: COMPLETED
-
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
NCT05210387 ·Status: TERMINATED ·Phase: NA
-
Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use
NCT03489330 ·Status: COMPLETED
-
Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)
NCT04434300 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit
NCT05696093 ·Status: RECRUITING ·Phase: PHASE3
-
Prophylactic Antibiotics on Urethral Catheter Withdrawal
NCT00126698 ·Status: COMPLETED ·Phase: PHASE4
-
PCR Technic Evaluation in the Microbial Diagnostic of Septicemia in Hemodialysis Patients With Catheter.
NCT04026035 ·Status: COMPLETED
-
Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii
NCT03622918 ·Status: COMPLETED ·Phase: NA